Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Sarcoma 2Plasma cell 2Tumor-Agnostic 1NET 1Endocrine 1CNS 1

Conditions

Carcinoma, Renal Cell 3Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

Magnetic Resonance Spectroscopy 98Specimen Handling 79pembrolizumab 75enzalutamide 63Nivolumab 59Gemcitabine 54Docetaxel 50apalutamide 42Radiosurgery 41Abiraterone Acetate 40Androgen Antagonists 39Prednisone 38Biopsy 37darolutamide 35Cisplatin 35cabozantinib 31Radiotherapy 31Carboplatin 28Pluvicto 27abiraterone 26enfortumab vedotin 24Ipilimumab 24Radiation 23durvalumab 22atezolizumab 22Leuprolide 20olaparib 18X-Rays 18Standard of Care 18avelumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
pazopanib × Genitourinary × 90 days × Clear all
NCT01575548 2026-05-29

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

National Cancer Institute (NCI)

Phase 3 Active not recruiting
129 enrolled 11 charts
Genitourinary

Carcinoma, Renal Cell

NCT03260894 2026-05-22

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Incyte Corporation

Phase 3 Completed
129 enrolled 13 charts
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT02555748 2026-03-31

SUP-R

Institut Claudius Regaud

Phase 4 Completed
47 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡